Browsing by Author "Öksüzoğlu, Berna"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    Publication
    Biologic subtypes and first relapse pattern in curative surgery performed breast cancer patients: Study of Anatolian Society of Medical Oncology
    (Lippincott Williams & Wilkins, 2013-05-20) Kaplan, Muhammet Ali; Arslan, Ülkü Yalçıntaş; Işıkdoğan, Abdurrahman; Öksüzoğlu, Berna; İnanç, Mevlüde; Akman, Tülay; İnal, Ali; Çankır, Havva Yeşil; Küçüköner, Mehmet; Budakoğlu, Burçin; Özkan, Metin; Yılmaz, Uğur; Baykara, Meltem; Yazılıtaş, Doğan; Ersoy, Uğur; Bilici, Mehmet; Çubukcu, Erdem; Yazıcı, Ozan; Suner, Ali; Demirci, Umut; ÇUBUKÇU, ERDEM; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; ETP-1691-2022
  • Thumbnail Image
    Item
    Biosimilar filgrastim vs filgrastim: A multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
    (Dove Medical Press, 2018) Sevinç, Alper; Özkan, Metin; Özet, Ahmet; Dane, Faysal; Öksüzoğlu, Berna; Işıkdoğan, Abdurrahman; Özdemir, Feyyaz; Uncu, Doğan; Gümüş, Mahmut; Yaren, Arzu; Kara, Oğuz; Tekin, Salim Başol; Evrensel, Türkkan; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-9732-5340; AAJ-1027-2021; 6603942124
    Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia. Patients and methods: This multicenter, observational study was conducted at 14 centers. The study included 337 patients experiencing neutropenia under chemotherapy. Patients were given either filgrastim 30 MIU or 48 MIU (Neupogen (R)) or biosimilar filgrastim 30 MIU (Leucostim (R)). Data regarding age, chemotherapeutic agents used, number of chemotherapy courses, previous diagnosis of neutropenia, neutrophil count of patients after treatment, medications used for the treatment of neutropenia, and duration of neutropenia were collected. Time to absolute neutrophil count (ANC) recovery was the primary efficacy measure. Results: Ambulatory and hospitalized patients comprised 11.3% and 45.1% of the enrolled patients, respectively, and a previous diagnosis of neutropenia was reported in 49.3% of the patients, as well. Neutropenia occurred in 13.7% (n=41), 45.5% (n=136), 27.4% (n=82), 11.4% (n=34), and 2.0% (n=6) of the patients during the first, second, third, fourth, and fifth cycles of chemotherapy, respectively. While the mean neutrophil count was 0.53 +/- 0.48 before treatment, a significant increase to 2.44 +/- 0.66 was observed after treatment (p=0.0001). While 90.3% of patients had a neutrophil count,1.49 before treatment, all patients had a neutrophil count >= 1.50 after treatment. Neutropenia resolved within <= 4 days of filgrastim therapy in 60.1%, 56.7%, and 52.6% of the patients receiving biosimilar filgrastim 30 MIU, original filgrastim 30 MIU, and original filgrastim 48 MIU, respectively. However, there was no significant difference between the three arms (p=0.468). Similarly, time to ANC recovery was comparable between the treatment arms (p=0.332). Conclusion: The results indicate that original filgrastim and biosimilar filgrastim have comparable efficacy in treating neutropenia. Biosimilar filgrastim provides a valuable alternative; however, there is need for further studies comparing the two products in different patient subpopulations.
  • Thumbnail Image
    Item
    Nutritional aspect of cancer care in medical oncology patients
    (Elsevier, 2019-11) Yalçın, Şuayib; Gümüş, Mahmut; Öksüzoğlu, Berna; Özdemir, Feyyaz; Sarıoğlu, Aysugül Alptekin; Şahin, Berksoy; Mandel, Nil Molinas; Göker, Erdem; Evrensel, Türkkan; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri/İç Hastalıkları Bölümü.; 0000-0002-9732-5340; AAJ-1027-2021; 6603942124
    Purpose: Awareness of advances in the nutritional aspects of cancer care and translation of this information into clinical practice are important for oncology practitioners to effectively couple oncologic and nutritional approaches throughout the cancer journey. The goal of this consensus statement by a panel of medical oncologists was to provide practical and implementable guidance addressing nutritional aspects of cancer care from the perspective of the medical oncologist. Methods: A panel of medical oncologists agreed on a series of statements supported by scientific evidence and expert clinical opinion. Findings: Participating experts emphasized that both poor nutritional intake and metabolic alterations underlie cancer-related malnutrition. The use of liquid and high energy-dense oral nutritional supplements may enable better patient compliance, whereas higher efficacy is more likely with the use of pharmaconutrient-enriched oral nutritional supplements in terms of improved weight, lean body mass, functional status, and quality of life, as well as better tolerance to antineoplastic treatment. A multimodal approach is currently believed to be the best option to counteract the catabolism leading to cancer-related malnutrition; this treatment is scheduled in parallel with anticancer therapies and includes nutritional interventions, multitarget drug therapies, and exercise and rehabilitation programs. Participating experts emphasized the role of the oncologist as a reference professional figure in the coordination of nutritional care for patients with cancer within the context of complex and different clinical scenarios, particularly for permissive-adjunctive nutritional support.
  • No Thumbnail Available
    Item
    Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
    (BMC, 2020-03-30) Yalçın, Şuayıb; Dane, Faysal; Öksüzoğlu, Berna; Özdemir, Nuriye Yıldırım; Özkan, Metin; Demirağ, Güzin Gönüllü; Coşkun, Hasan Şenol; Karabulut, Bülent; Ustaoglu, Mehmet Ali; Özdemir, Feyyaz; Turna, Hande; Yavuzşen, Tuğba; Aykan, Faruk; Sevinç, Alper; Akbulut, Hakan; Yüce, Deniz; Hayran, Mutlu; Kılıçkap, Saadettin; Evrensel, Türkkan; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları.; 0000-0002-9732-5340; AAJ-1027-2021; 6603942124
    BackgroundCombination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown.MethodsA total of 125 patients were randomized to combination therapy (1000mg/m2 gemcitabine +125mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000mg/m2) arms to take treatment weekly for 7 of 8weeks, and following 3 of 4weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL.ResultsOverall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p=0.018). These proportions were 27.3 and 36.6% in 6(th) month assessments, respectively (p=0.357). Median overall survivals in combination and single-agent arms were 9.92months and 5.95months, respectively (HR: 0.64, 95% CI: 0.42-0.86, p=0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22months, respectively (HR: 0.58, 95% CI: 0.39-0.87, p=0.008). Median time-to-deterioration were 5.36 vs 3.68months, and objective response rates were 37.1% vs 23.7% (p=0.009), respectively in combination and single-agent arms.ConclusionsCombination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer.Trial registrationThis study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered).